Heart Doc VIP with Dr. Joel Kahn Dr. Joel Kahn

This week Dr. Kahn was overloaded with important new science and discussed the risks of early menopause in women and the dangers of low testosterone levels in men. A concerning report on a rise in early colorectal cancer under age 45 is discussed. Two headline studies on the weight loss drug Wegovy (semiglutide) improving weight long term and improving heart failure measurements are hopeful. A massive "umbrella review" reported lower heart and cancer risks with plant-based diets.
The main topic is about the implications of the coronary artery calcium score (CACS), in this case in healthy people over age 75. The CACS may be the best test of "biological age" available as the new study reports.

In this episode of Heart Doc VIP, Dr. Joel Kahn reflects on a heartfelt Mother’s Day and dives into a smorgasbord of health-focused topics. From the ins and outs of hormone replacement therapy and the mighty power of CoQ10, to understanding apoB and the benefits of edamame and hemp seeds for managing blood pressure. We’ll also sprinkle some truth about dietary salt and explore the risks linked to Alzheimer's disease.
But that’s just the appetizer! Our main course serves up an in-depth look at intensive cardiac rehabilitation programs designed by pioneers like Pritikin and Ornish. Beyond the treadmill, these programs integrate mind-body practices and plant-based nutrition. Could these comprehensive approaches be the secret sauce to lasting heart health? Tune in to discover how these intensive regimens could not just add years to your life, but life to your years.
And don’t forget to check out www.thrivemarket.com, as recommended by Dr. Kahn, to further enrich your journey toward optimal health.

Join Dr. Kahn as he dives into the world of cardiovascular health and nutrition with the legendary Dr. Caldwell Esselstyn from the Cleveland Clinic. At 90, Dr. Esselstyn is not only defying age but also continuing to inspire countless people with his work. Tune in to hear this insightful conversation filled with respect and admiration for a true pioneer in medicine.

In this episode, Dr. Kahn kicks off with some motivating insights from recent research showing that climbing stairs can lower death rates. He then explores two new studies highlighting the benefits of creatine and roasted green tea (hojicha) for brain performance. Find creatine here: Dr. Joel Kahn's Creatine Capsules.
Dr. Kahn also delves into the roles of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in health and disease, focusing on Laron Syndrome. This rare condition involves life-long low levels of IGF-1, leading to shorter stature but also lower rates of diabetes, cancer, and heart disease. He discusses how the Prolon Fasting Mimicking Diet and the new L-Protein can help regulate IGF-1 for better health. Check them out here: Prolon FMD by Dr. Kahn.

This week, Dr. Kahn explores a variety of "mini-topics," including the presence of microplastics in fish, the link between heart disease and cancer, the ineffectiveness of the ketogenic diet for cardiovascular disease, and the lifetime risk and consequences of atrial fibrillation.
Dr. Kahn also embraces the theme of "fighting heart disease like cancer" by presenting case studies from two recent patients at the Kahn Center for Cardiac Longevity, showcasing the center's approach to aggressive treatment that mirrors cancer care norms.

Welcome to Heart Doc VIP! This week, Dr. Kahn tackles a series of mini-topics including the use of colchicine in treating heart disease, the crucial role of oral health in managing atrial fibrillation, and why beta-blockers may not benefit many heart attack patients.
Plus, hear Dr. Kahn's thoughts on Valter Longo, Ph.D.'s insights about the "5Ps" that are excessively present in our diets. Also, check out the newly available L-Protein, a plant-based protein, at prolonfmd.com/Drkahn.
Our main discussion centers on the recent findings from the TACT2 trial, where intravenous chelation therapy in 1,000 heart patients followed over four years failed to improve outcomes. This result is particularly disheartening following the promising TACT trial published in 2013, and it likely signals the end of funded research for chelation therapy.